drugset / Trial / NCT05216237
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as First-line or second-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer. At the same time, the correlation between tissue programmed death ligand-1(PD-L1) expression and blood circulating tumor cell(CTC) counts and the efficacy of immune combination therapy was also explored.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2024-06-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 40 mg | Oral |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 50 mg/m2 | Oral |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 60 mg | Oral |